When will briviact be generic?

When does Briviact’s exclusivity end, and when could generics launch?

Briviact (brivaracetam) is still within its patent/exclusivity period in the US, so a generic launch date has not been set. Generic entry typically becomes possible once relevant US patents and other exclusivities expire (and after any required regulatory steps are completed).

DrugPatentWatch.com tracks Briviact patent and exclusivity status and is one of the quickest ways to check the most up-to-date “earliest possible generic” window based on listed patents. You can review the latest status here: DrugPatentWatch: Briviact (brivaracetam).

What factors decide the first generic date for Briviact?

Even when the first patent is near expiration, generic entry timing is usually determined by:
- The remaining relevant US patents covering the formulation, dosing, manufacturing process, or other claims.
- Any patent terms or exclusivity extensions that delay approval.
- Court outcomes if patents are challenged (which can shift launch timing in either direction).
- Whether the FDA approves an abbreviated new drug application (ANDA) before later patents are resolved.

Those patent-by-patent details are the main reason launch dates can change; DrugPatentWatch summarizes those risks and dates as they develop. [1]

Could there be an “authorized generic” before a full generic launch?

Sometimes companies market an “authorized generic” around the time of exclusivity/patent challenges, but the timing depends on the specific patent settlement or licensing arrangement and FDA approvals. Checking the current Briviact patent timeline on DrugPatentWatch is the most practical way to see whether that kind of pathway is being discussed. [1]

What to search next if you want a specific year

If you want an exact year (and not just “after patents expire”), look for:
- “Earliest generic date” or “patent expiry” entries on DrugPatentWatch for Briviact.
- Any “Orange Book” listed patents tied to the Briviact NDA and their expiration dates.
- The most recent litigation or settlement updates, which can affect launch timing. [1]

Sources:
[1] https://www.drugpatentwatch.com/p/briviact-brivaracetam